Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identiifed
10.3779/j.issn.1009-3419.2015.12.04
- VernacularTitle:盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
- Author:
LI XI
1
;
QIN NA
;
WANG JINGHUI
;
YANG XINJIE
;
ZHANG XINYONG
;
LV JIALIN
;
WU YUHUA
;
ZHANG HUI
;
NONG JINGYING
;
ZHANG QUAN
;
ZHANG SHUCAI
Author Information
1. 首都医科大学附属北京胸科医院肿瘤内科
- Keywords:
Lung neoplasms;
Icotinib hydrochloride;
EGFR mutation;
Treatment outcome
- From:
Chinese Journal of Lung Cancer
2015;(12):734-739
- CountryChina
- Language:Chinese
-
Abstract:
Background and objectiveIcotinib is the ifrst self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, geiftinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the effcacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients withEGFR mutation and wild-type.MethodsPatients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014.Re-sults hTe clinical data of 124 patients (99 withEGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. hTe patients’ overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; hTe patients withEGFR mutation, ORR was 63.6%, DCR was 93.9%. hTe ORR was 4.0% and the DCR was 24.0% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment inEGFR mutation patients was 10.5 months and 1.0 month in wild-type patients. hTe major adverse events were mild skin rash (30.6%) and diarrhea (16.1%).Conclusion Monotherapy with icotinib hydrochloride is effective and tolerable for the advanced NSCLCEGFR mutation patients.
